Allarity Posts $6.2M Q3 Loss as Going-Concern Doubt Deepens
ALLR sits 24% above its 52-week low of $0.769.
Summary
Allarity reported a $6.2 million net loss for the third quarter. The number lands alongside the 10-Q filed today, which discloses substantial doubt about the company's ability to continue as a going concern and negative stockholders' equity that breaches Nasdaq's $2.5 million minimum. The company has been shrinking its obligations: it terminated the $6.0 million Tumim equity line on October 28 and settled a $4.9 million Novartis liability for $1 million in cash on November 2. A post-quarter $3.0 million raise is noted in the filing, and the company sees a full-year loss per share of 73 cents to 76 cents. At a roughly $14.5 million market cap the loss is large relative to the equity base and the going-concern language is the real story.
At the time of this announcement, ALLR was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.5M. The 52-week trading range was $0.77 to $1.84. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.